N-(4-(4-(4-methoxybenzyl)-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide | 1334921-47-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-(4-(4-methoxybenzyl)-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide
• 英文别名: N-[4-[4-[(4-methoxyphenyl)methyl]-2,6-dimethylphenyl]-1,3-thiazol-2-yl]pyridine-4-carboxamide
• CAS: 1334921-47-9
• 化学式: C₂₅H₂₃N₃O₂S
• 分子量: 429.543
• InChiKey: ILXXCNQLKQLLNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-methoxylbenzylzinc(II) bromide 、 N-[5-(4-iodo-2,6-dimethylphenyl)thiazol-2-yl]isonicotinamide 在 四(三苯基膦)钯 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以73%的产率得到N-(4-(4-(4-methoxybenzyl)-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide
  参考文献：
  名称：

  Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy

  摘要：

  Highly expressed in cancer 1 (Hec1) plays an essential role in mitosis and is correlated with cancer formation, progression, and survival. Phosphorylation of Hec1 by Nek2 kinase is essential for its mitotic function, thus any disruption of Hec1/Nek2 protein-protein interaction has potential for cancer therapy. We have developed T-1101 tosylate (9j tosylate, 9j formerly known as TAI-95), optimized from 4-aryl-N-pyridinylcarbonyl-2-aminothiazole of scaffold 9 by introducing various C-4' substituents to enhance potency and water solubility, as a first-in-class oral clinical candidate for Hec1 inhibition with potential for cancer therapy. T-1101 has good oral absorption, along with potent in vitro antiproliferative activity (IC50: 14.8-21.5 nM). It can achieve high concentrations in Huh-7 and MDA-MB-231 tumor tissues, and showed promise in antitumor activity in mice bearing human tumor xenografts of liver cancer (Huh-7), as well as of breast cancer (BT474, MDA-MB-231, and MCF7) with oral administration. Oral co-administration of T-1101 halved the dose of sorafenib (25 mg/kg to 12.5 mg/kg) required to exhibit comparable in vivo activity towards Huh-7 xenografts. Cellular events resulting from Hec1/Nek2 inhibition with T-1101 treatment include Nek2 degradation, chromosomal misalignment, and apoptotic cell death. A combination of T-1101 with either of doxorubicin, paclitaxel, and topotecan in select cancer cells also resulted in synergistic effects. Inactivity of T-1101 on non-cancerous cells, a panel of kinases, and hERG demonstrates cancer specificity, target specificity, and cardiac safety, respectively. Subsequent salt screening showed that T-1101 tosylate has good oral AUC (62.5 mu M.h), bioavailability (F = 77.4%), and thermal stability. T-1101 tosylate is currently in phase I clinical trials as an orally administered drug for cancer therapy. (c) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112118

文献信息

• Modulators Of HEC1 Activity And Methods Therefor
  申请人：Lau Johnson

  公开号：US20110230486A1

  公开（公告）日：2011-09-22

  Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Especially preferred compounds disrupt Nek2/Hec1 binding and are therefore useful as chemotherapeutic agent for neoplastic diseases.

  提供了用于调节Hec1/Nek2相互作用的化合物、组合物和方法。特别偏爱的化合物会破坏Nek2/Hec1的结合，因此可用作肿瘤疾病的化疗药物。
• [EN] IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR<br/>[FR] MODULATEURS AMÉLIORÉS DE L'ACTIVITÉ HEC1 ET PROCÉDÉS ASSOCIÉS
  申请人：TAIVEX THERAPEUTICS CORP

  公开号：WO2013082324A1

  公开（公告）日：2013-06-06

  Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.

  提供了用于调节Hec1/Nek2相互作用的化合物、组合物和方法。这些化合物破坏了Nek2/Hec1的结合，并可能作为抗肿瘤疾病的化疗药物有用。
• Modulators of HEC1 activity and methods therefor
  申请人：Lau Johnson

  公开号：US08946268B2

  公开（公告）日：2015-02-03

  Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Especially preferred compounds disrupt Nek2/Hec1 binding and are therefore useful as chemotherapeutic agent for neoplastic diseases.

  本发明提供了调节Hec1/Nek2相互作用的化合物、组合物和方法。特别优选的化合物破坏Nek2/Hec1结合，因此可用作肿瘤疾病的化疗药物。
• MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR
  申请人：HUANG Jiann-Jyh

  公开号：US20130190312A1

  公开（公告）日：2013-07-25

  Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.

  提供了调节Hec1/Nek2相互作用的化合物、组合物和方法。这些化合物破坏Nek2/Hec1结合，可能作为肿瘤治疗药物有用。
• Modulators of Hec1 activity and methods therefor
  申请人：Taivex Therapeutics Corporation

  公开号：US08999983B2

  公开（公告）日：2015-04-07

  Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Such compounds disrupt Nek2/Hec1 binding and may be useful as chemotherapeutic agents for neoplastic diseases.

  提供了调节Hec1/Nek2相互作用的化合物、组合物和方法。这些化合物破坏Nek2/Hec1结合，可能作为治疗肿瘤疾病的化疗药物有用。